Investment Thesis
Akari Therapeutics is a pre-revenue pharmaceutical company facing critical financial distress with zero cash on hand, negative operating cash flow of -$10.6M, and a current ratio of 0.44x indicating severe liquidity crisis. The company cannot fund ongoing operations or R&D without immediate capital infusion, making near-term solvency a material risk regardless of pipeline potential.
Strengths
- Operating losses improved 12.6% YoY, indicating marginal trend improvement
- Debt-free capital structure with no long-term debt obligations
- Modest total asset base of $47.9M suggests some underlying value
Risks
- Zero cash and equivalents with -$10.6M operating cash burn - immediate liquidity crisis
- Current ratio of 0.44x indicates inability to cover short-term liabilities; working capital severely negative
- No revenue generation and pre-revenue stage requires continuous external funding with no clear path to profitability
- Deeply negative ROE (-61.1%) and ROA (-36.1%) reflect value destruction
- Pharmaceutical development timelines are long; cash runway appears exhausted
Key Metrics to Watch
- Cash position and burn rate - critical for survival assessment
- Any capital raises or financing announcements - necessary for operational continuity
- Clinical trial progression and regulatory pathway for pipeline drugs
Financial Metrics
Revenue
N/A
Net Income
-17.3M
EPS (Diluted)
$0.00
Free Cash Flow
-10.6M
Total Assets
47.9M
Cash
0.0
Profitability Ratios
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
ROE
-61.1%
ROA
-36.1%
FCF Margin
N/A
Balance Sheet & Liquidity
Current Ratio
0.44x
Quick Ratio
0.44x
Debt/Equity
0.00x
Debt/Assets
40.9%
Interest Coverage
-172.75x
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-15T08:33:49.345991 |
Data as of: 2025-12-31 |
Powered by Claude AI